CA2589252A1 - Ameliorant for renal insufficiency - Google Patents

Ameliorant for renal insufficiency Download PDF

Info

Publication number
CA2589252A1
CA2589252A1 CA002589252A CA2589252A CA2589252A1 CA 2589252 A1 CA2589252 A1 CA 2589252A1 CA 002589252 A CA002589252 A CA 002589252A CA 2589252 A CA2589252 A CA 2589252A CA 2589252 A1 CA2589252 A1 CA 2589252A1
Authority
CA
Canada
Prior art keywords
agent
renal dysfunction
improving renal
carbon atoms
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002589252A
Other languages
French (fr)
Other versions
CA2589252C (en
Inventor
Keisuke Sato
Motoaki Saito
Bang Luu
Masashi Yamada
Hiroto Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Meiji Co Ltd
Original Assignee
Meiji Dairies Corporation
Keisuke Sato
Motoaki Saito
Bang Luu
Masashi Yamada
Hiroto Suzuki
Meiji Co., Ltd.
Centre National De La Recherche Scientific (Cnrs)
Strasbourg University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corporation, Keisuke Sato, Motoaki Saito, Bang Luu, Masashi Yamada, Hiroto Suzuki, Meiji Co., Ltd., Centre National De La Recherche Scientific (Cnrs), Strasbourg University filed Critical Meiji Dairies Corporation
Publication of CA2589252A1 publication Critical patent/CA2589252A1/en
Application granted granted Critical
Publication of CA2589252C publication Critical patent/CA2589252C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

The present invention relates to an agent for improving renal dysfunction comprising as an active ingredient a compound represented by the following formula (1): wherein each R 1 , R 2 , and R 3 represents a hydrogen atom or a methyl group, and X represents a linear or branched alkylene or alkenylene group having 10 to 28 carbon atoms.

Claims (6)

1. An agent for improving renal dysfunction comprising as an active ingredient a compound represented by the following formula (1):

wherein each R1, R2, and R3 represents a hydrogen atom or a methyl group and X represents a linear or branched alkylene or alkenylene group having 10 to 28 carbon atoms.
2. The agent for improving renal dysfunction according to claim 1, wherein X is a linear alkylene group having 10 to 28 carbon atoms.
3. The agent for improving renal dysfunction according to claim 2, wherein X is a linear alkylene group having 10 to 18 carbon atoms.
4. The agent for improving renal dysfunction according to any one of claims 1 to 3, wherein at least one of R1, R2, and R3 is a methyl group.
5. The agent for improving renal dysfunction according to claim 4, wherein each R1, R2, and R3 represents a methyl group.
6. Use of a compound represented by the following formula (1):

wherein each R1, R2, and R3 represents a hydrogen atom or a methyl group and X represents a linear or branched alkylene or alkenylene group having 10 to 28 carbon atoms, for the manufacture of an agent for improving renal dysfunction.
CA2589252A 2004-11-25 2005-11-25 Ameliorant for renal insufficiency Expired - Fee Related CA2589252C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004-341019 2004-11-25
JP2004341019 2004-11-25
PCT/JP2005/021705 WO2006057346A1 (en) 2004-11-25 2005-11-25 Ameliorant for renal insufficiency

Publications (2)

Publication Number Publication Date
CA2589252A1 true CA2589252A1 (en) 2006-06-01
CA2589252C CA2589252C (en) 2012-12-04

Family

ID=36498079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2589252A Expired - Fee Related CA2589252C (en) 2004-11-25 2005-11-25 Ameliorant for renal insufficiency

Country Status (10)

Country Link
US (2) US20080125495A1 (en)
EP (1) EP1829536B1 (en)
JP (1) JP4869078B2 (en)
KR (1) KR101169633B1 (en)
CN (1) CN101065119B (en)
AT (1) ATE503471T1 (en)
CA (1) CA2589252C (en)
DE (1) DE602005027246D1 (en)
ES (1) ES2361847T3 (en)
WO (1) WO2006057346A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080312336A1 (en) * 2005-05-26 2008-12-18 Keisuke Satoh Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder
JP4986505B2 (en) * 2005-05-26 2012-07-25 株式会社明治 Preventive and / or therapeutic agent for diabetic vascular disorder and respiratory disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5697223A (en) * 1979-12-30 1981-08-05 Takeda Chem Ind Ltd Tissue metabolism activator
CA2334709A1 (en) * 1998-06-11 1999-12-16 Fox Chase Cancer Center Method for assessing a diabetic's risk of experiencing a diabetes-associated pathologic condition
JP2000083623A (en) * 1998-09-10 2000-03-28 Nobuko Koga Food
JP4469441B2 (en) * 1999-02-10 2010-05-26 明治乳業株式会社 Preventive or therapeutic agents for neurodegenerative diseases
WO2002029014A2 (en) * 2000-10-04 2002-04-11 Meiji Dairies Corporation Stem cell differentiation-inducing promoter
JP4861560B2 (en) * 2001-02-19 2012-01-25 株式会社明治 Treatment for diabetic complications
JP3836684B2 (en) 2001-02-19 2006-10-25 明治乳業株式会社 Treatment for dysuria
JP2004000115A (en) * 2001-09-07 2004-01-08 Mitsuo Itakura Method for judging development risk of diabetes

Also Published As

Publication number Publication date
KR101169633B1 (en) 2012-07-31
ES2361847T3 (en) 2011-06-22
CA2589252C (en) 2012-12-04
US20080125495A1 (en) 2008-05-29
EP1829536A4 (en) 2009-08-12
CN101065119B (en) 2010-08-25
JP4869078B2 (en) 2012-02-01
CN101065119A (en) 2007-10-31
EP1829536B1 (en) 2011-03-30
KR20070089922A (en) 2007-09-04
DE602005027246D1 (en) 2011-05-12
WO2006057346A1 (en) 2006-06-01
ATE503471T1 (en) 2011-04-15
EP1829536A1 (en) 2007-09-05
JPWO2006057346A1 (en) 2008-06-05
US20120136068A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
TW200730496A (en) Oxime ester photoinitiators
ATE302001T1 (en) STABILIZED ASCORBIC ACID DERIVATIVES
CA2561406A1 (en) Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component
EP1241528A3 (en) Radical polymerizable compounds for image forming materials
TWI263632B (en) Quaternary ammonium salt, electrolyte and electrochemical device
TW200641539A (en) Salt suitable for an acid generator and a chemically amplified resist composition containing the same
EP1849788A8 (en) Organosilicon compound
EA200870321A1 (en) Method of producing 4-oxyquinoline compound
CA2445395A1 (en) Heterocyclic compound and antitumor agent comprising the same as effective component
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
EP1908759A3 (en) 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation
TW200706694A (en) Water-soluble preflux and use thereof
MX2010001344A (en) Phenylacetic acid compound.
CA2528122A1 (en) Trans-1,2-cyclohexane bis[urea-urethane] compounds
JP2004535412A5 (en)
DE60228990D1 (en) BICYCLIC CONNECTION
MY158003A (en) Antibacterial 3',5-disubtituted 2,4'-dihydroproxybiphenyl compounds, derivatives and related methods
EP0879841A3 (en) Silicon compound, method for making the same, and electroluminescent device using the same
CA2589252A1 (en) Ameliorant for renal insufficiency
WO2008149701A1 (en) Radiation-sensitive resin composition
EP2165709A3 (en) Lysine based compounds
CA2583699A1 (en) Stat3 phosphorylation inhibitor and notch1 expression inhibitor
EP1645916A3 (en) Electrostatic charge image developing toner

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151125